Abstract 200P
Background
Malignant Mixed Mullerian Tumor (MMMT) also known as carcinosarcoma is considered as a rare aggressive biphasic tumor with carcinomatous and sarcomatous elements found in postmenopausal women, uterus being the most common site, followed by cervix, vagina, and rarely adnexa or vulva. It usually presents at an advanced stage and lacks specific treatment guidelines requiring a multimodality approach with surgery and chemoradiation (CTRT) for better prognosis & outcomes. The aim was to study the patterns of failure and overall survival in patients treated with different modalities.
Methods
An observational analysis of 82 patients from the year 2015-2019 was done including demographic data such as age and ECOG status. The patients were staged based on the FIGO 2019 system after imaging and histopathological examination. The different treatment regimens with surgery and lymph node dissection (LND), CTRT used as definitive or adjuvant therapy was noted. This study shows the impact of surgery and CTRT on overall survival (OS), progression free survival (PFS) and disease specific survival (DSS) according to stage and type of treatment. We conducted Kaplan-Meier method with log-rank tests for comparison of prognostic factors with survival and Cox proportional hazard model for both univariate and multivariate analysis considering p values <0.05 to be statistically significant. The median follow-up period was 35 months (4-76).
Results
The OS rate was 37.8% with a median of 28 months (95% CI: 22.3-33.6), a better OS was present by 34 months (95% CI: 17.18-50.81) in patients who had received adjuvant CTRT, 12 months (95% CI: 9-15) with definitive CTRT, while 7 months (95% CI: 4-10) with only surgery. There was a statistically significant improvement (p-0.001) in overall survival rate by 65.5% for those who underwent both LND with radiation. The PFS rate was 58.5% with a median of 47 months; stage I-IIIC with both surgery and CTRT had a better PFS and DSS by 64.3% and 46.4% respectively (p-0.001).
Conclusions
Patients receiving stagewise combined modality approach with both surgery and CTRT for management had a significantly better OS, PFS and DSS in comparison to with only single mode of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
196P - Short course brachytherapy in locally advanced cervical cancer: Safety and response rate
Presenter: Maryam Garousi
Session: Poster viewing 03
197P - The risk of uterine cervical cancer in inflammatory bowel disease: An updated systematic review and meta-analysis
Presenter: Hee Man Kim
Session: Poster viewing 03
198P - Geographic and demographic access to brachytherapy in India, with a special emphasis on gynaecological cancers
Presenter: Abhishek Krishna
Session: Poster viewing 03
199P - Prevalence of cervical cancer in Uzbekistan: A population based study
Presenter: Sayde Djanklich
Session: Poster viewing 03
201P - Immunotherapy in advanced mismatch repair deficiency endometrial cancer: A real-world single center experience
Presenter: Amit Rauthan
Session: Poster viewing 03
203TiP - Autophagy as a target for therapy in ovarian cancer: A phase II randomized trial with biomarker correlation (ATOC Trial)
Presenter: Luxitaa Goenka
Session: Poster viewing 03
210P - Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays
Presenter: Lei Chen
Session: Poster viewing 03
211P - Chemotherapy delivery time affects anti-lymphoma treatment outcome in a sex-dependent manner
Presenter: Yeonsoo Park
Session: Poster viewing 03